Granahan Investment Management LLC Increases Holdings in Celcuity, Inc. $CELC

Granahan Investment Management LLC raised its position in shares of Celcuity, Inc. (NASDAQ:CELC) by 76.6% during the 4th quarter, HoldingsChannel.com reports. The fund owned 87,032 shares of the company’s stock after acquiring an additional 37,751 shares during the period. Granahan Investment Management LLC’s holdings in Celcuity were worth $8,681,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of CELC. EverSource Wealth Advisors LLC boosted its position in Celcuity by 1,329.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after acquiring an additional 319 shares in the last quarter. US Bancorp DE boosted its position in Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after acquiring an additional 143 shares in the last quarter. BNP Paribas Financial Markets boosted its position in Celcuity by 78.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after acquiring an additional 1,167 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in Celcuity during the 4th quarter valued at approximately $42,000. Finally, Ogorek Anthony Joseph NY ADV boosted its position in Celcuity by 19.7% during the 4th quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company’s stock valued at $66,000 after acquiring an additional 109 shares in the last quarter. 63.33% of the stock is owned by institutional investors.

Insider Buying and Selling at Celcuity

In other Celcuity news, Director David Dalvey sold 25,000 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.68, for a total value of $3,517,000.00. Following the completion of the sale, the director owned 65,000 shares in the company, valued at approximately $9,144,200. This represents a 27.78% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.46, for a total value of $1,264,140.00. Following the completion of the sale, the director owned 6,760 shares of the company’s stock, valued at $949,509.60. The trade was a 57.11% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 37,000 shares of company stock valued at $5,111,950 over the last 90 days. 13.33% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Wolfe Research reaffirmed an “outperform” rating and set a $110.00 price objective on shares of Celcuity in a research report on Thursday, March 12th. Wells Fargo & Company cut their price objective on Celcuity from $183.00 to $166.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 3rd. Guggenheim reissued a “buy” rating on shares of Celcuity in a research report on Wednesday, June 3rd. Craig Hallum dropped their price target on Celcuity from $189.00 to $171.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. Finally, Stifel Nicolaus set a $150.00 price target on Celcuity in a research report on Monday, May 4th. Eleven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $152.09.

Celcuity Price Performance

Shares of CELC opened at $87.32 on Wednesday. The firm has a market cap of $4.26 billion, a PE ratio of -22.39 and a beta of 0.10. The company has a current ratio of 12.31, a quick ratio of 12.31 and a debt-to-equity ratio of 6.04. The firm has a fifty day simple moving average of $118.82 and a two-hundred day simple moving average of $111.13. Celcuity, Inc. has a 1-year low of $11.27 and a 1-year high of $151.02.

Celcuity (NASDAQ:CELC) last announced its earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.10. On average, equities analysts anticipate that Celcuity, Inc. will post -3.69 EPS for the current year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.